Endocrine 2 Flashcards

1
Q

DM1

A
Autoimmune
Pancreatic beta cells destroyed
(Islets of Langerhans)
No insulin produced
Glucose ^^^
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

DM2

A

Excess adipose tissue
Relative insulin deficiency
Glucose ^

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prediabetes

A

Not meeting DM2 criteria
Likely to develop DM2 in next few years
Require lifestyle interventions

Fasting glucose 6.1-6.9
HbA1c 42-47

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

DM2 risk factors

A

Age ^
Family history
Non-white

Sedentary lifestyle
Obesity
Stress

GDM
PCOS

HTN
Dyslipidaemia
CVD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

DM clinical features

A

Polydipsia
Polyuria
Weight loss
Fatigue

Visual disturbances
Abdo pain
N/V

Recurrent infections

  • Candidal
  • Skin
  • UTI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Polydipsia/polyuria pathophysiology

A

Glycosuria
Water follows by osmosis
= Dehydration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

DM investigations

A

Random plasma glucose > 11

Fasting plasma glucose > 6.9

OGTT - 75g glucose - Wait 2 hours - Positive > 11

HbA1c > 48

Urine dip - Ketones +++

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

DM1 management

A

Insulin

  • SC pump
  • 0.2-0.4 units/kg/day
  • BM self-monitoring
  • Pre-meal insulin correction dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

DM2 management - Lifestyle

A

Lifestyle changes (HbA1c 48-53)

  • Weight loss 5-10%
  • Physical activity
  • Reduce alcohol intake - Risk of hypo
  • Smoking cessation

Diet - Reduce sugar consumption

  • High fibre
  • Low GI foods
  • Low-fat dairy produts
  • Reduced saturated fats and TFAs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

DM sick day rules

A
Increase frequency of BM monitoring
Increase fluid intake - 3L / 24 hours
Maintain carbohydrate intake - Sugary drinks if necessary
Access to a mobile phone 
Continue medication - Except metformin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DM indications for admission

A
Inability to tolerate oral fluids
Persistent diarrhoea
Significant ketosis - Despite additional insulin
BM > 20 - Despite additional insulin
Lack of support at home
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DM2 management

A
  1. HbA1c 48-53 - Diet and exercise
  2. Metformin
  3. If HbA1c > 58 add…
    - Gliptin
    - Sulfonylurea
    - Pioglitazone
    - SGLT-2 inhibitor - Gliflozin
  4. If HbA1c > 58 - Add another
  5. If HbA1c > 58 and BMI > 35
    - Add GLP-1 mimetic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

DM drugs MoA

A

Metformin - CI if eGFR < 30

  • Increases insulin sensitivity
  • Decreases hepatic gluconeogenesis

Sulfonylurea - Gliclazide

  • Risk of hypoglycaemia
  • Stimulates pancreatic B cells to produce insulin

Pioglitazone

  • Promote adipogenesis and FFA uptake
  • Weight gain

Gliptins

  • Increases incretin
  • Inhibits glucagon secretion
  • Risk of pancreatitis

SGLT-2 inhibitors - Inhibits renal reabsorption of glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

DM complications

A

Microvascular

  • Neuropathy
  • Retinopathy
  • Neuropathy

Macrovascular

  • CVD
  • CHF
  • Stroke

Infection
DKA
Non-ketotic hyperosmolar state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

DKA pathophysiology

A

Insulin deficiency + Glucagon ^
Triglycerides and AAs metabolised for energy
Increased serum glycerol and FFA
Glucagon converts FFA to ketones

Hyperglycaemia causes osmotic diuresis
Marked urinary loss of water and electrolytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

DKA clinical features

A

N/V
Abdo pain

Altered consciousness
Dehydration

Hyperventilation - Kussmaul breathing
Ketone breath - Pear drops

Sx of DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

DKA investigations

A

VBG

  • Hyperkalaemia
  • Hypokalaemia = Severe DKA
  • Metabolic acidosis
  • Serum osmolality ^^^

pH < 7.3
Serum ketones > 3
BM > 11
Bicarb < 15

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

DKA management

A

Fluid replacement

  • 500ml bolus over 10-15 minutes
  • 1L over 1 hour

Correct hypokalaemia - SandoK
Insulin - FR infusion

When glucose < 14 - Give 10% Dextrose

Safe rate of glucose reduction - 4-6 mmol/hr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

DKA complications

A

Arrhythmias - Hypo/hyperkalaemia
VTE

ARDS
Gastric stasis
AKI

Cerebral oedema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Hyperosmolar hyperglycaemic state pathophysiology

A
Hyperglycaemia
Osmotic diuresis
- Electrolyte abnormalities 
- Severe dehydration 
- Raised serum osmolality
- Hyperviscosity

Typically elderly DM2 patients
Develops over many days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Hyperosmolar hyperglycaemic state clinical features

A

Dehydration
Hypotension
Tachycardia

Fatigue
Lethargy
Weakness
Altered consciousness

N/V
Headaches
Papilloedema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Hyperosmolar hyperglycaemic state diagnosis criteria and management

A
  1. Hypovolaemia
  2. Hyperglycaemia > 30 ± Ketonaemia/acidosis
  3. Serum osmolality > 320

Management

  • Fluid replacement
  • Correct electrolyte abnormalities
  • Normalise blood glucose
23
Q

Thyroid storm precipitating events

A

MIST

Media - Contrast - Acute iodine load
Infection
Surgery
Trauma

24
Q

Thyroid storm clinical features

A

Fever > 38.5

Tachycardia
Hypertension
HF

Confusion and agitation
N/V

Abnormal LFTs
Jaundice

25
Q

Thyroid storm management

A

Symptomatic - Paracetamol
BBs - IV propranolol

Carbimazole
Dex - Blocks conversion of T3 to T4

26
Q

Myxoedema coma

Symptoms and management

A

Confusion
Hypothermia

Management

  • IV thyroxine
  • IV Fluid replacement
  • IV corticosteroids
  • Correct electrolyte imbalance
  • Rewarming?
27
Q

Thyroid cancers

A

Presentation - Thyroid nodule in a woman aged 30-50

Papillary carcinoma - 70%

  • Young females
  • Excellent prognosis

Follicular adenoma - 20%
- Solitary thyroid nodule

Medullary carcinoma - 5%

  • Secrete calcitonin
  • 20% familial genetics

Anaplastic carcinoma - 1%

  • Pressure symptoms
  • Elderly females
  • Chemo ineffective

Lymphoma - Associated with Hashimoto’s

28
Q

Thyroid nodule investigations

A

TSH - Normal
USS + FNB

Laryngoscopy - Paralysed vocal cord?

CT staging

Serum calcitonin - Medullary carcinoma

29
Q

Thyroid cancer management

A

Total thyroidectomy
Radioiodine ablation

TSH suppression - Levothyroxine

Screen for recurrence - Yearly thyroglobulin levels

30
Q

Hypoadrenalism

A

Primary

  • TB
  • Metastases
  • Meningococcal septicaemia
  • HIV
  • Antiphospholipid syndrome

Secondary - Pituitary disorders

  • Tumours
  • Irradiation
  • Infiltration
31
Q

Pituitary adenoma risk factors

A

MEN-1
Familial isolated pituitary tumours - FIPA
Carney complex - CNC

32
Q

Pituitary adenoma clinical features

A

Headaches
Bitemporal hemianopia

Central adiposity
Reduced muscle mass

Hypogonadism

  • Gynaecomastia
  • Amenorrhoea
  • Infertility
  • Loss of libido
  • ED

Hypothyroidism
Fatigue
Osteopenia

Adrenal insufficiency

  • Anorexia
  • N/V
  • Weakness
33
Q

Pituitary adenoma investigations

A

Prolactin ^
IGF-1 - Low with GH deficiency

Sex hormones - LH, FSH, testosterone, oestrogen

Morning cortisol
ACTH
ACTH stimulation test

Insulin tolerance test

U&E - Hyponatraemia
FBC - Anaemia

CT/MRI

34
Q

Pituitary adenoma management

A

Pituitary apoplexy

  • Hydrocortisone
  • Levothyroxine
  • Trans-sphenoidal resection

Adenoma

  • Observation
  • Hormone replacement
  • Radiotherapy
  • Dopamine agonist - Bromocriptine / Cabergoline
  • Somatostatin analogue - Octreotide
35
Q

PTH physiology and vit D synthesis

A

PTH released in response to low Ca

  • Increased bone resorption by OCs - More Ca released
  • Increased Ca reabsorption in kidneys
  • Increased vit D synthesis in kidney
  • Increased calcium and phosphate absorption from gut

25-hydroxyvitamin D
Converted to 1,25-dihydroxyvitamin D
Absorbed in gut

36
Q

HyperPTH aetiology

A

Primary - Solitary adenoma
Secondary - Hyperplasia

Risk factors

  • Female
  • Age > 50
  • Family history
  • MEN
  • Li treatment
37
Q

HyperPTH clinical features

A

= Hypercalcaemia

Bones - Osteoporosis, osteopenia, pain 
Stones - Renal
Moans - Depression and anxiety
Groans - Abdominal pain and myalgia
Thrones - Constipation

Sleep disturbances
Fatigue
Cognitive changes
Paraesthesia

38
Q

HyperPTH investigations

A

Calcium profile

  • Calcium ^ (Low in 2)
  • Phosphate ^ (Low in 2)
  • PTH ^
  • ALP ^

Tech-99 scan
ECG - Short QT

Skeletal survey - Pepper pot skull
Knee XR - Chondrocalcinosis

39
Q

HyperPTH management

A

Parathyroidectomy

+ Vit D supplementation - Ergocalciferol
+ Alendronic acid
+ Cinacalcet

40
Q

HypoPTH aetiology

A

Thyroid/parathyroid surgery

Malnutrition
Malabsorption
Diarrhoea

Chronic alcoholism

Hypomagnesaemia

AD conditions - CASR and GATA3

41
Q

HypoPTH clinical features

A

Secondary to hypocalcaemia

Tetany - Muscle twitches, spasms, cramps
Perioral paraesthesia
Trosseau’s sign - Carpal spasm on inflation of BP cuff
Chvostek’s sign - Tapping parotid causes facial muscles to twitch

Depression
Cognitive changes
Anxiety
Dry hair and brittle nails
Cataracts
42
Q

HypoPTH investigations and management

A

Calcium profile

  • Ca - LOW
  • PTH - LOW
  • Phosphate ^
  • Vit D - LOW

Albumin

  • Low albumin will falsely lower serum calcium
  • Ionised calcium accurately reflects physiological calcium

Magnesium - LOW
ECG - Prolonged QT

Management

  • Calcium carbonate
  • Calcitriol
43
Q

Hypernatraemia aetiology

A

Dehydration
Osmotic diuresis
DI

Infancy
Old age

Renal concentrating deficit

Iatrogenic

  • IV saline
  • Lithium
  • Mannitol
44
Q

Hypernatraemia clinical features

A

CNS manifestations

  • Lethargy/weakness
  • Irritability
  • IC haemorrhage
  • Seizures
  • Stupor
  • Coma

Weight loss - Hypovolaemia
Hypo/tachy
Decreased JVP
Dry mucous membranes

45
Q

Hypernatraemia investigations and management

A

Serum sodium

Urine osmolality

  • Low - DI
  • High - Volume depletion

Serum osmolality - High

Management - Treat cause

  • Fluid replacement
  • DI - Desmopressin / Thiazide diuretic
46
Q

Carcinoid syndrome aetiology

A

Metastases in the liver
Serotonin released into systemic circulation

Risk factors - MEN-1

47
Q

Carcinoid syndrome clinical features

A

Flushing
Palpitations

Diarrhoea
Abdo cramps

Signs of RHF
Cardiac murmurs
Hepatomegaly

48
Q

Carcinoid syndrome investigations and management

A

Serum chromogranin A/B ^^^
Urinary 5-hydroxyindoleacetic acid ^^^

Creatinine ^^^
LFTs

Management - Somatostatin analogue - Octreotide

49
Q

Multiple endocrine neoplasia

A
MEN-1 - 3Ps
- Parathyroid
- Pituitary
- Pancreas 
\+ Adrenal
\+ Thyroid

MEN-2a - 2Ps - RET oncogene

  • Medullary thyroid cancer
  • Parathyroid
  • Phaeochromocytoma

MEN-2b - 1P - RET oncogene

  • Phaeochromocytoma
  • Marfanoid body habitus
  • Neuromas
50
Q

Phaeochromocytoma

A

Catecholamine secreting tumour

Associated with

  • MEN-2
  • Neurofibromatosis
  • Von-Hippel Lindau syndrome

10% rule

  • Familial in 10%
  • Bilateral in 10%
  • Malignant in 10%
  • Extra-adrenal in 10% - Organ of Zuckerlandl
51
Q

Phaeochromocytoma clinical features

A

HTN - 90%

  1. Headaches
  2. Palpitations
  3. Diaphoresis
Hypertensive retinopathy
Pallor
DM
Orthostatic hypotension
Cafe au lait spots
52
Q

Phaeochromocytoma investigations

A

24-hour urine collection

  • Catecholamines
  • Metanephrines
  • Normetanephrines
  • Creatinine

MRI - Adrenal medulla
Genetic testing

53
Q

Phaeochromocytoma management

A

AB - Phenoxybenzamine
BB - Propranolol

+ Surgical excision